- Home
- NERV vs CANF Comparison
NERV vs CANF Comparison
Compare NERV & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- CANF
- Stock Information
- Founded
- NERV 2007
- CANF 1994
- Country
- NERV United States
- CANF Israel
- Employees
- NERV N/A
- CANF N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- CANF Health Care
- Exchange
- NERV Nasdaq
- CANF Nasdaq
- Market Cap
- NERV 12.0M
- CANF 9.6M
- IPO Year
- NERV 2014
- CANF N/A
- Fundamental
- Price
- NERV $2.15
- CANF $0.65
- Analyst Decision
- NERV Hold
- CANF Strong Buy
- Analyst Count
- NERV 1
- CANF 2
- Target Price
- NERV $5.00
- CANF $14.50
- AVG Volume (30 Days)
- NERV 12.9K
- CANF 171.1K
- Earning Date
- NERV 11-04-2025
- CANF 08-26-2025
- Dividend Yield
- NERV N/A
- CANF N/A
- EPS Growth
- NERV N/A
- CANF N/A
- EPS
- NERV 1.48
- CANF N/A
- Revenue
- NERV N/A
- CANF $560,000.00
- Revenue This Year
- NERV N/A
- CANF $461.72
- Revenue Next Year
- NERV N/A
- CANF N/A
- P/E Ratio
- NERV $1.46
- CANF N/A
- Revenue Growth
- NERV N/A
- CANF N/A
- 52 Week Low
- NERV $1.15
- CANF $0.63
- 52 Week High
- NERV $2.98
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- NERV 48.19
- CANF 36.38
- Support Level
- NERV $2.06
- CANF $0.64
- Resistance Level
- NERV $2.25
- CANF $0.68
- Average True Range (ATR)
- NERV 0.11
- CANF 0.02
- MACD
- NERV -0.03
- CANF 0.01
- Stochastic Oscillator
- NERV 24.19
- CANF 50.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).